A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone acetate; Enzalutamide; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CARD
- Sponsors Sanofi
- 24 Nov 2017 Planned End Date changed from 1 Jun 2018 to 27 Dec 2018.
- 24 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 27 Dec 2018.
- 10 Jun 2017 Biomarkers information updated